Trial-by-gene · NTRK1/2/3
Active trials enrolling NTRK fusion-positive solid tumors
Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.
NTRK fusion-positive cancer trials focus on (1) post-first-generation TKI resistance (especially solvent-front G595R/G623R), where repotrectinib retains activity, (2) next-generation TRK inhibitors covering broader resistance mutation spectra, and (3) rare-tumor expansion cohorts (infantile fibrosarcoma, MASC, secretory breast carcinoma).
See the NTRK cheat sheet.
Browse the live listing
Search ClinicalTrials.gov for actively recruiting trials with NTRK fusion eligibility across tumor types.
Open ClinicalTrials.gov listingSource: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.
Representative trial phases and designs
Phase I/II, post-TKI
Repotrectinib (TRIDENT-1) NTRK expansion cohorts; next-gen TRK inhibitors after larotrectinib/entrectinib.
Pediatric expansion
Larotrectinib in pediatric NTRK fusion-positive tumors (infantile fibrosarcoma, others).
Frequently asked questions
- Are NTRK trials open to all solid tumors?
- Most are tumor-agnostic per the regulatory pathway, but some require specific histologies for cohort expansion or eligibility.